National Pharmaceutical Pricing Authority Current Affairs - 2020
On April 1, 2020, the National Pharmaceutical Pricing Authority revised the ceiling price of 883 scheduled formulations. The authority also informed that the disruption of supply of Active Pharmaceutical Ingredients are returning to normalcy.
The NPPA has notified 24 classes of medical devices as drugs under Drugs and Cosmetics Act, 1940. The prices of other non-scheduled medical devices are being monitored by the authority. The authority has also come up with a ruling that no manufacturers or importers shall increase the price of these listed devices by not more than 10% for another 12 months.
The devices are to be monitored and treated as drug for quality control and price monitoring.
Active Pharmaceutical Ingredient
The Active Pharmaceutical Ingredient is that part of the drug that produces the intended effects. Some of the drugs have multiple APIs to treat different symptoms.
India believes that Indian APIs should get US FDA approval. This is because, exporting a US FDA approved API is easier all over the world. This is because, several drug companies believe and import FDA approved APIs.
Tags: APIs • Ceiling Price • COVID-19 • Drug Price Control Orders • Drugs
Government has notified that ceiling price of orthopaedic knee implants will be monitored to ensure that their cost does not increase beyond 10% in a given year.
Earlier on 16 August 2017, National Pharmaceutical Pricing Authority (NPPA) notified ceiling price of orthopaedic knee implants by invoking extraordinary powers, in public interest, under Para 19 of Drugs Prices Control Order (DPCO) 2013, for a period of 1 year. Subsequently a notification was issued dated 13 August 2018, the applicability of ceiling prices fixed for orthopaedic knee implants was extended for another 1 year period i.e. up to 15 August 2019.
This led to the reduction in cost of knee implants significantly, up to 69%, resulting in a notional saving of Rs.1500 crore per annum to consumers.
At a meeting held on 8 August 2019, NPPA reviewed the sales of knee implants matter and noted that there has been an increased access due to knee implants becoming affordable. As per data submitted by manufacturers and importers, during period of July 2018 to June 2019, an increase of 30% in sales of knee implants was reported.
Though the medical industry has requested for a 20% (10% for year 2018 and 10% for 2019) increase in price of knee implants, government decided to further monitor price increase of knee implants as per para 20 of Drugs Prices Control Order (DPCO) 2013 that restricts price increase beyond 10% in a given year which shall be subject to a review after 1 year period.
About Knee Implant:
It is a non-scheduled medical device or drug for which Drugs Prices Control Order (DPCO), 2013 allows an annual increase upto 10% of MRP (Maximum retail price). However this was not permitted in 2018.
What is National Pharmaceutical Pricing Authority?
NPPA is independent body of experts that controls prices of pharmaceutical drugs in India. It is government regulatory agency formed on 29 August 1997.
It functions under Union Ministry of Chemicals and Fertilizers to implement and enforce provisions of Drugs Prices Control Order (DPCO) for regulating medicine prices in accordance with powers delegated to it.
DPCO is an order issued by government under ‘Essential Commodities Act’ which enables it to fix prices of some essential bulk drugs as well as their formulations.